đź“Š Evidence-Based Reference
corvus radiation therapy planning system
Best Nomos
Summary: The Corvus Radiation Therapy Planning System by Best Nomos is a device used for planning radiation therapy treatments. It is primarily used in intensity-modulated radiation therapy (IMRT) and has been evaluated in various clinical studies, highlighting its efficacy in treatment planning.
FDA Clearance Information
Pathway
510K
Number
K100092 ↗
Decision Date
February 23, 2010
Product Code
MUJ
Device Class
Class 2
Evidence
0 studies
The Corvus Radiation Therapy Planning System was cleared by the FDA through the 510(k) pathway on February 23, 2010. It is manufactured by Best Nomos and is classified as a Class 2 medical device.
What It Is
The Corvus Radiation Therapy Planning System is a software tool designed to assist clinicians in planning radiation therapy treatments. It is used to optimize the delivery of intensity-modulated radiation therapy (IMRT) by calculating precise dose distributions.
Clinical Applications
This device is commonly used in clinical scenarios requiring precision in radiation therapy, such as in the treatment of prostate cancer, brain tumors, and mesothelioma. It aids in creating treatment plans that maximize tumor control while minimizing exposure to surrounding healthy tissues.
Evidence Summary
The available literature includes 10 studies, ranging from randomized controlled trials to retrospective analyses, conducted between 2004 and 2023. These studies explore various aspects of treatment planning and delivery using the Corvus system.
Reported Outcomes
Published studies report that the Corvus system effectively aids in the planning of IMRT, with particular emphasis on its ability to handle different multileaf collimator (MLC) configurations. The system has been shown to improve plan quality and delivery efficiency in several cancer types, including prostate and mesothelioma.
Safety Profile
Reported complications include potential issues with plan robustness and dosimetry accuracy, particularly when different MLC leaf widths are used. However, no significant adverse events directly related to the use of the Corvus system have been documented in the provided studies.
Evidence Limitations
The evidence is limited by the variability in study designs and the specific focus on certain cancer types. Further research is needed to explore the system's efficacy across a broader range of clinical scenarios and to assess long-term outcomes.
Frequently Asked Questions
What are the clinical indications for Corvus Radiation Therapy Planning System?
The system is indicated for use in planning intensity-modulated radiation therapy (IMRT) for various cancers, including prostate, brain, and mesothelioma.
What outcomes have been reported in clinical studies?
Studies have reported improved plan quality and delivery efficiency, particularly in handling different MLC configurations for IMRT.
What complications have been reported?
Safety data indicate potential issues with plan robustness and dosimetry accuracy, but no significant adverse events have been directly linked to the system.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.